Healthcare EBITDA Multiples: 2026 Dashboard

Healthcare M&A is entering 2026 in a period of measured recalibration. Transaction volume has moderated from the post-pandemic surge, but capital flows remain substantial, and buyer selectivity has sharpened rather than retreated. The premium threshold for deal-making has risen: buyers are prioritizing platforms with demonstrated operating leverage, defensible reimbursement models, and exposure to outpatient and technology-enabled care delivery. For sellers and their advisors, understanding where multiples sit today, and why, is the starting point for any credible transaction strategy.

Across all sectors, the global median EV/EBITDA multiple for M&A transactions recovered to 9.7x on a trailing-twelve-month basis through Q3 2025, up from 9.3x earlier in the year, with the U.S. market running above that figure at 10.6x.¹ Healthcare, however, historically trades at a meaningful premium to the cross-sector median, driven by its essential-service profile, non-discretionary demand, and favorable long-term demographics.

Broad Healthcare M&A Valuation Trends

The table below tracks headline EV/EBITDA multiples across the healthcare sector over recent periods, reflecting data from publicly disclosed transactions in North America.

The divergence between PE and strategic buyer multiples in Q1 2025 is notable. According to the R.L. Hulett Q1 2025 Report, median private equity EV/EBITDA of 18.3x (the highest recorded in five years) reflects PE’s appetite for high-conviction platforms in a period where dry powder remains plentiful, and healthcare is viewed as a recession-resilient sector.³ Strategic buyers, by contrast, showed greater pricing discipline, gravitating toward bolt-on transactions at lower multiples as corporate balance sheets absorbed earlier deal integrations.

By Q1 2026, the median TEV/EBITDA across disclosed healthcare M&A transactions multiple compressed further to 12.7x, down from 13.0x a year prior and 14.9x in Q1 2024.² This compression is broadly consistent with a more selective financing environment and sustained buyer scrutiny of reimbursement risk. The TEV/Revenue figure of 3.04x marks the lowest level in four years, signaling that revenue quality, particularly visibility and payer mix stability, is being priced with increasing precision.²

Multiple Trends by Subsector

Not all healthcare subsectors are experiencing the same valuation dynamics. Technology-enabled services and biopharma are responding to distinct macro forces, while provider services show wider variance by segment and scale.

Biopharma presents the starkest shift. The average EV/EBITDA for pharma M&A deals in 2025 fell to approximately 15x from roughly 25x in 2024, as policy uncertainty compressed valuations and acquirers increasingly structured deals with contingent value rights (CVRs) tied to clinical milestones rather than paying full value upfront.¹ ⁴

Meanwhile, Healthcare IT platforms continue to attract the strongest multiples across services, buoyed by escalating demand for AI-enabled revenue cycle management, prior authorization automation, and ambient clinical documentation.⁴

Home-Based Care: EBITDA Multiples by Segment

Home health, hospice, and home care represent one of the most active consolidation corridors in healthcare. Deal volume in the home health and hospice sector hit 110 transactions in 2025, surpassing 2024’s total of 97 deals.⁷ Private equity activity in home-based care expanded 53.6% year-over-year in 2025, with 11 new platform investments and 32 add-on acquisitions.⁶ The table below breaks down observed EBITDA multiples by service type.

Hospice commands the highest multiples in the segment, driven by certificate-of-need protections in applicable states, favorable average length-of-stay dynamics, and growing patient preference for home-based end-of-life care among aging Medicare beneficiaries. Behavioral health and ABA (applied behavior analysis) follow closely, supported by chronic demand-supply imbalance and telehealth integration.⁶ ⁷

One important nuance: reimbursement headwinds in home health are real. CMS’s Calendar Year 2026 Home Health Prospective Payment System Final Rule reduces payments in the aggregate by approximately 1.3%, or $220 million, compared with 2025, a figure less severe than the 6.4% cut feared earlier in 2025, but still material for smaller independent agencies with thin margins.⁷ The result is a divergence between distressed smaller operators trading at compressed multiples and well-capitalized regional platforms continuing to attract premium bids.

Mental and Behavioral Health: A Closer Look

Behavioral health stands apart for the breadth of its M&A activity in 2025. According to LevinPro HC, the sector recorded 104 deals in 2025, a 42% increase over 2024 and the highest volume since 2022, with momentum expected to carry into 2026.⁷ The structural driver is straightforward: more than 122 million Americans live in a federally designated Health Professional Shortage Area for mental health care.⁷

For mid-market platforms (typically $3M–$20M EBITDA), multiples generally land in the 7x–12x range depending on scale, payer mix, and service acuity. Smaller independent mental health clinics see a wider and lower range. HealthFMV’s analysis of small-to-medium-sized mental health providers places typical transaction multiples at 4x–8x EBITDA, with cash-flow multiples for smaller owner-operated practices ranging from approximately 2.4x to 4.6x at the 25th and 75th percentiles, and a median of 3.1x.⁵

CMS is actively supporting integration of behavioral health and primary care through the 2026 Physician Fee Schedule, increasing payment rates for providers offering integrated services — a policy tailwind that is already influencing deal activity.⁷

What Drives Premium Valuations in 2026

Across subsectors, buyers are applying consistent frameworks to distinguish premium assets from the broader pool. Key premium factors include:

2026 Outlook

Healthcare M&A is not expected to broadly re-rate to 2021 peak multiples, but several subsectors are positioned for multiple expansion in 2026. PitchBook’s 2026 Healthcare Outlook projects a rebound in biopharma M&A activity as policy uncertainty clears and additional rate cuts spur more speculative investing, while healthtech and Healthcare IT are forecast to maintain strength driven by AI-enabled platforms and payer cost management demand.⁴ eHealth transactions reached a three-year high in 2025 at 299 deals, a 21% increase over the prior year, with RCM firms emerging as a particularly active target category (54 deals in 2025 alone).⁷

The most durable theme threading through all of these markets: buyers are not deploying capital broadly. They are concentrating on platforms where AI integration, reimbursement defensibility, and operational leverage converge, and they are paying accordingly.

Requesting a Copy of This Report

FOCUS Investment Banking specializes in maximizing transaction value for healthcare business owners through our proven quarterback approach to M&A advisory. Our team has completed more than 30 transactions for physician groups, dental practices, behavioral health organizations, and related healthcare services companies.

If you would like to learn more about how current market conditions may affect the valuation of your practice, or to request a PDF copy of this report, you can reach out to Eric Yetter ([email protected]) or Andy Snyder ([email protected]).

Sources